⮝ Full datasets listing
PXD078170
PXD078170 is an original dataset announced via ProteomeXchange.
Dataset Summary
| Title | NLRC4 promotes PANoptosis to overcome sorafenib resistance in hepatocellular carcinoma by competitively binding to BCLAF1 with TRIB3 |
| Description | Objective: Hepatocellular carcinoma (HCC) is a leading global cause of cancer death with poor prognosis. Sorafenib is the therapeutic agent for HCC, but its clinical efficacy is severely compromised by drug resistance. PANoptosis has been reported to be associated with sorafenib-induced cell death. However, the role of the PANoptosis-related gene NLRC4 in sorafenib-resistant HCC remains unclear. This study aimed to investigate the regulatory role of NLRC4 in PANoptosis in sorafenib-resistant HCC and the underlying mechanisms. Methods: We assessed the role of NLRC4 in regulating PANoptosis in sorafenib-resistant HCC cells using overexpression and knockdown experiments. Then, we performed mass spectrometry and multi-omics to explore the downstream mechanisms of NLRC4 in regulating PANoptosis. Results: These results demonstrate that NLRC4 inhibits cell proliferation and promotes PANoptosis to overcome sorafenib resistance in HCC cells. Further mechanistic studies revealed that NLRC4 interacts with BCLAF1, compromising BCLAF1 stability, thereby strengthening PANoptosis. Transcriptomics and proteomics revealed that TRIB3 is a downstream target of NLRC4, and NLRC4 reduces TRIB3 expression. TRIB3 has been reported to form a complex with BCLAF1. Based on these results, we hypothesized and demonstrated that NLRC4 competitively binds to TRIB3 and modulates BCLAF1 stability to regulate PANoptosis and sensitivity to sorafenib in HCC cells. Conclusion: NLRC4 suppresses HCC sorafenib resistance by promoting PANoptosis though competitively bind to BCLAF1 with TRIB3. These findings suggest the regulatory role of NLRC4 in PANoptosis and offer a potential therapeutic strategy for overcoming sorafenib-resistant HCC. |
| HostingRepository | iProX |
| AnnounceDate | 2026-05-08 |
| AnnouncementXML | Submission_2026-05-08_18:03:00.414.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Qi Li |
| SpeciesList | scientific name: Homo sapiens; NCBI TaxID: 9606; |
| ModificationList | No PTMs are included in the dataset |
| Instrument | Orbitrap Astral |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
|---|---|---|---|
| 0 | 2026-05-08 18:02:05 | ID requested | |
| ⏵ 1 | 2026-05-08 18:03:01 | announced |
Publication List
| Dataset with its publication pending |
Keyword List
| submitter keyword: Hepatocellular carcinoma, sorafenib resistance, NLRC4 |
| PANoptosis |
Contact List
| Zhongjun Wu | |
|---|---|
| contact affiliation | The First Affiliated Hospital of Chongqing Medical University |
| contact email | zjytcy@126.com |
| lab head | |
| Qi Li | |
| contact affiliation | The First Affiliated Hospital of Chongqing Medical University |
| contact email | liqi_092001@163.com |
| dataset submitter | |
Full Dataset Link List
| iProX dataset URI |
